Fighting Drug Resistance in Giardia intestinalis: In Vitro Testing of Novel Antibiotics

Tyler Smith, LJ McKenzie, Dallin Harper, Lacey Wayment, John Thurston, Danny Xu, Ken Cornell

Research output: Contribution to conferencePresentation

Abstract

Annually, more than 280 million people worldwide develop symptomatic Giardia intestinalis (GI) infections, making it one of the most prevalent parasitic diseases. The parasite colonizes the small intestine, causing diarrhea, stomach cramps, vomiting, weight loss, and fatigue. While rarely fatal, the interruption of nutrient absorption can cause developmental delays in children. The current treatment generally relies on nitroazole drugs like metronidazole (MTZ), tinidazole, and albendazole. Drug resistance is a pressing issue, making the development of alternative treatments important. Our prior work has shown that the parasite enzyme 5’ Methylthioadenosine nucleosidase (MTN) is a good target for drug development. MTN inhibition would interrupt critical methionine and adenine recycling in GI, leading to cell death. In silico screening of potential MTN binding drugs has identified a set of thirty-three possible inhibitors that could ultimately have antiparasitic activity. Preliminary in vitro cytotoxicity data indicate that four compounds out of the thirty-three potential MTN inhibitors show micromolar IC 50 values. These compounds will serve as leads for future drug optimization and testing against both MTZ sensitive and MTZ resistant parasites to examine their ability to overcome drug resistant infections.

Original languageAmerican English
StatePublished - 12 Jul 2018

Fingerprint

Dive into the research topics of 'Fighting Drug Resistance in Giardia intestinalis: In Vitro Testing of Novel Antibiotics'. Together they form a unique fingerprint.

Cite this